Lauric Acid Derivative Compositions for Broad-Spectrum Antimicrobial Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antimicrobial agents, particularly medium chain fatty acids like lauric acid, face challenges in effectively targeting both gram-positive and gram-negative pathogens, especially antibiotic-resistant strains, due to limited solubility, metabolic breakdown when ingested, and inconsistent bacteriostatic/bactericidal activity, making them unsuitable for internal use against harmful pathogens.

Innovation Solution

Development of medium chain fatty acid derivative compositions that include active components such as dodecanoic acid and its derivatives, which are formulated to improve solubility, stability, and specificity, allowing for internal use as direct-acting small molecule agents that can inhibit or kill both gram-positive and gram-negative pathogens, including antibiotic-resistant strains, by altering their chemical form and combining with lecithin and chitosan to create particulated compositions with enhanced antimicrobial activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If medium chain fatty acids like lauric acid are used as antimicrobial agents, then antimicrobial activity is achieved, but solubility is limited and metabolic breakdown occurs when ingested

Engineering Contradiction:

Improveantimicrobial activityVSAvoidsolubility and metabolic stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses cyclodextrins as intermediary molecules to complex with medium chain fatty acids. The cyclodextrin-fatty acid complex improves solubility in aqueous environments and protects the fatty acid from metabolic breakdown, allowing internal use while maintaining antimicrobial activity

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates composite formulations combining medium chain fatty acids with cyclodextrins and other carriers. This composite approach enhances both solubility and stability while preserving the antimicrobial properties of the fatty acid component

Inventive Principle:

Principle #40Composite materials

2Adaptability or versatility

If medium chain fatty acids are used to target both gram-positive and gram-negative pathogens, then broad spectrum activity is achieved, but inconsistent bacteriostatic/bactericidal activity occurs

Engineering Contradiction:

Improvebroad spectrum activityVSAvoidconsistent antimicrobial activity

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent modifies key parameters including pH, concentration, and the chemical form of medium chain fatty acids through cyclodextrin complexation. These parameter changes enable consistent bactericidal activity across both gram-positive and gram-negative pathogens by optimizing the fatty acid's ability to interact with different bacterial cell membranes

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If medium chain fatty acids are formulated for internal use, then safety profile is improved, but metabolic breakdown reduces effectiveness

Engineering Contradiction:

Improvesafety profileVSAvoideffectiveness against pathogens

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

Cyclodextrins serve as protective intermediaries that shield medium chain fatty acids from metabolic enzymes in the gastrointestinal tract. This protection allows the fatty acids to reach their target pathogens intact, maintaining effectiveness while enabling safe internal administration

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20220296549A1Small Molecule Agents, Compositions, and Formulations, for Internal Use, Displaying Inhibitory Activity Against Gram-positive and/or Gram-negative Organisms

Publication Date: 2022.09.22 NATUREZA RESEARCH INC

AI summary

Active components comprising lauric acid, or a lauric acid derivative, are utilized independently, or in combination, to provide new and useful compositions for bacteriostatic action against susceptible pathogens. The lauric acid derivative includes one or more of 12-aminododecanoic acid, 12-amino-1-dodecanoic acid methyl ester, sucrose monolaurate, 12-(7-nitrobenzofurazan-4-ylamino) dodecanoic acid, 4-nitrophenyl dodecanoate, 1-lauroyl-rac-glycerol, 3-oxo-N-(2-oxocyclohexyl) dodecanamide, butyl laurate, benzyl laurate, isoamyl laurate, monolaurin, isopropyl laurate, pentyl laurate, and hexyl laurate. A preparation includes combining the active component with lecithin, and after an initial processing phase, coating with chitosan or a carrier. Final compositions may be or may contain particles, such as nanoparticles. Final compositions, or formulations containing said final compositions, may be utilized internally, causing one or more membrane changes (e.g., a membrane of an internal target pathogen, which may or may not be an antibiotic-resistant pathogen). At least some compositions inhibit growth of one or more Gram-positive bacterial species and one or more Gram-negative bacterial species.